100 Recruiting Studies Using Ruxolitinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Ruxolitinib
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
π University of Alabama At Birmingham β Birmingham, Alabama
Myelofibrosis
View Study & Checklist βStudy of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
π Ironwood Cancer & Res Ctr /ID# 222162 β Chandler, Arizona
Myelofibrosis (MF)
View Study & Checklist βA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
π City of Hope /ID# 239769 β Duarte, California
Myeloproliferative Neoplasm
View Study & Checklist βStudy of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
π Tom Baker Cancer Centre β Calgary, Alberta
Myelofibrosis
View Study & Checklist βCINC424A2X01B Rollover Protocol
π Novartis Investigative Site β Darlinghurst, New South Wales
Primary Myelofibrosis
View Study & Checklist βStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
π UAB Division of Hematology/Oncology β Birmingham, Alabama
Myelofibrosis
View Study & Checklist βKRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
π The Kirklin Clinic of UAB Hospital β Birmingham, Alabama
Polycythemia Vera
View Study & Checklist βRuxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
π H. Lee Moffitt Cancer Center and Research Institute β Tampa, Florida
Chronic Myelomonocytic Leukemia
View Study & Checklist βTreatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
π H. Lee Moffitt Cancer Center and Research Institute β Tampa, Florida
Chronic Phase Chronic Myeloid Leukemia
View Study & Checklist βPeritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Primary Myelofibrosis
View Study & Checklist βStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
π Investigative Site US020 β Phoenix, Arizona
Hidradenitis Suppurativa
View Study & Checklist βPhase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
π University of Alabama at Birmingham β Birmingham, Alabama
Myelofibrosis
View Study & Checklist βUse Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
π Phoenix Children's Hospital β Phoenix, Arizona
Hemophagocytic Lymphohistiocytosis
View Study & Checklist βRuxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Aplastic Anemia
View Study & Checklist βStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
π Investigative Site US257 β Birmingham, Alabama
Hidradenitis Suppurativa
View Study & Checklist βINCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
π City of Hope National Medical Center β Duarte, California
Anemia
View Study & Checklist βCART123 + Ruxolitinib in Relapsed/Refractory AML
π University of Pennsylvania β Philadelphia, Pennsylvania
Relapsed AML
View Study & Checklist βAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
π UCLA Healthcare Hematology-Oncology β Santa Monica, California
Pancreatic Cancer
View Study & Checklist βA Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
π Mayo Clinic Hospital β Phoenix, Arizona
Chronic Graft-versus-host-disease
View Study & Checklist βSafety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
π University of California, Davis Comprehensive Cancer Center /ID# 221790 β Sacramento, California
Myelofibrosis (MF)
View Study & Checklist βA Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
π Clinical Research Center of Alabama β Birmingham, Alabama
Atopic Dermatitis
View Study & Checklist βA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
π Local Institution - 0069 β Newport Beach, California
Myelofibrosis
View Study & Checklist βA Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
π Royal Brisbane and Women'S Hospital β Herston, Queensland
Myeloproliferative Neoplasms
View Study & Checklist βRuxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
π City of Hope Cancer Center β Duarte, California
Other Cancer
View Study & Checklist βVSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
π Mayo Clinic in Rochester β Rochester, Minnesota
Metastatic Endometrial Carcinoma
View Study & Checklist βEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
π Ironwood Cancer and Research Center β Chandler, Arizona
Carcinoma, Non-Small-Cell Lung
View Study & Checklist βTotal Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
π Lucile Packard Children's Hospital Stanford University β Palo Alto, California
Acute Lymphoblastic Leukemia
View Study & Checklist βA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
π City of Hope β Duarte, California
Myelofibrosis
View Study & Checklist βTyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
π National Institutes of Health Clinical Center β Bethesda, Maryland
Eosinophilic Myeloid Neoplasm
View Study & Checklist βA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
π Memorial Sloan Kettering Monmouth β Middletown, New Jersey
Myelofibrosis
View Study & Checklist βDe-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
π Froedtert Hospital & the Medical College of Wisconsin β Milwaukee, Wisconsin
Graft-versus-host Disease
View Study & Checklist βAdding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
π Memorial Sloan Kettering Cancer Center β New York, New York
Acute Lymphoblastic Leukemia
View Study & Checklist βReduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
π Stanford University β Stanford, California
Allogeneic Hematopoietic Cell Transplantation (HCT)
View Study & Checklist βTesting the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
π Anchorage Associates in Radiation Medicine β Anchorage, Alaska
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
View Study & Checklist βA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
π Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) β Glendale, Arizona
Essential Thrombocythemia
View Study & Checklist βRuxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
π M D Anderson Cancer Center β Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist βJAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
π National Institutes of Health Clinical Center β Bethesda, Maryland
Severe Aplastic Anemia
View Study & Checklist βRuxolitinib + Allogeneic Stem Cell Transplantation in AML
π Beth Israel Deaconess Medical Center β Boston, Massachusetts
Acute Myeloid Leukemia
View Study & Checklist βBelumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure
π University Health Network β Toronto, Ontario
cGVHD
View Study & Checklist βOpzelura Experience Study
π Wake Forest University Health Sciences β Winston-Salem, North Carolina
Atopic Dermatitis
View Study & Checklist βUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
π University of California, San Francisco β San Francisco, California
Psoriasis
View Study & Checklist βTolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
π Huntsman Cancer Institute at University of Utah β Salt Lake City, Utah
Myelofibrosis
View Study & Checklist βRevumenib in Patients With Myelofibrosis
π Icahn School of Medicine at the Mount Sinai Hospital β New York, New York
Myelofibrosis
View Study & Checklist βA Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
π University of Alabama At Birmingham-School of Medicine β Birmingham, Alabama
NonSegmental Vitiligo
View Study & Checklist βA Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Hematologic Malignancies
View Study & Checklist βA Study of Ruxolitinib and Duvelisib in People With Lymphoma
π University of Miami (Data Collection Only) β Miami, Florida
T-cell Lymphomas
View Study & Checklist βRuxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
π University of Chicago Medical Center β Chicago, Illinois
Acute Lymphoblastic Leukemia
View Study & Checklist βStudy to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
π Syneos Health (remote site) β Morrisville, North Carolina
Pregnancy Related
View Study & Checklist βStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
π Saguaro Dermatology β Phoenix, Arizona
Hidradenitis Suppurativa
View Study & Checklist βRuxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
π Dana-Farber Cancer Institute β Boston, Massachusetts
T-Cell Large Granular Lymphocyte Leukemia
View Study & Checklist βRuxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
π Washington University School of Medicine β St Louis, Missouri
Graft Vs Host Disease
View Study & Checklist βStudy to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
π INNO-6051 Site 03 β Fredericton, New Brunswick
Discoid Lupus Erythematosus
View Study & Checklist βRetifanlimab and Ruxolitinib In Solid Malignancies
π University of California, San Diego Moores Cancer Center β La Jolla, California
Non Small Cell Lung Carcinoma
View Study & Checklist βA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
π Yale University School Of Medicine β New Haven, Connecticut
Primary Myelofibrosis (PMF)
View Study & Checklist βNeratinib in Combination With Ruxolitinib in Patients With mTNBC
π Baylor University Medical Center, Baylor Charles A Sammons Cancer Center β Dallas, Texas
Metastatic Triple-Negative Breast Carcinoma
View Study & Checklist βA Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
π City of Hope β Duarte, California
Neoplasms
View Study & Checklist βPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist βAmping up With PemJAK
π Columbia University Irving Medical Center β New York, New York
Non-Hodgkin Lymphoma
View Study & Checklist βRuxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
π Stanford Cancer Institute Palo Alto β Palo Alto, California
BCR-JAK2 Fusion Protein Expression
View Study & Checklist βOlutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
π MD Anderson Cancer Center β Houston, Texas
Targeted Therapy
View Study & Checklist βTopical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
π Cleveland Clinic β Cleveland, Ohio
Dermatomyositis
View Study & Checklist βNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
π University of Illinois Cancer Center β Chicago, Illinois
Hodgkin Lymphoma
View Study & Checklist βA Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
π The University of Texas M. D. Anderson Cancer Center β Houston, Texas
AML
View Study & Checklist βRuxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
View Study & Checklist βA Trial of Selinexor, Ruxolitinib and Methylprednisolone
π Berenson Cancer Center β West Hollywood, California
Multiple Myeloma in Relapse
View Study & Checklist βA Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
π Global Oncology, Inc. β Alhambra, California
Multiple Myeloma
View Study & Checklist βRuxolitinib in Thrombocythemia and Polycythemia Vera
π Massachusetts General Hospital β Boston, Massachusetts
Essential Thrombocythemia
View Study & Checklist βActive Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
π Moffitt Cancer Center β Tampa, Florida
MDS/MPN
View Study & Checklist βMAGIC Ruxolitinib for aGVHD
π City of Hope Comprehensive Cancer Center β Duarte, California
Acute Graft-versus-host Disease
View Study & Checklist βA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
π University of Alabama β Birmingham, Alabama
Myelofibrosis
View Study & Checklist βRuxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
π City of Hope Medical Center β Duarte, California
Follicular Helper T-Cell Lymphoma
View Study & Checklist βA Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
π City of Hope Medical Center β Duarte, California
Myeloproliferative Neoplasms
View Study & Checklist βA Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
π Axis Clinicals β Dilworth, Minnesota
Healthy Participants
View Study & Checklist βA Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
π Massachusetts General Hospital (Data Collection Only) β Boston, Massachusetts
Myelofibrosis
View Study & Checklist βBiomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
π City of Hope Medical Center β Duarte, California
Hematopoietic and Lymphatic System Neoplasm
View Study & Checklist βRuxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
π University of Pennsylvania β Philadelphia, Pennsylvania
Castleman's Disease (CD)
View Study & Checklist βStudy of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
π University of Miami β Miami, Florida
Lymphoma
View Study & Checklist βRuxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
π OHSU Knight Cancer Institute β Portland, Oregon
Acute Myeloid Leukemia
View Study & Checklist βRuxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
π Baptist Health Herbert Wertheim Cancer Institute β Miami, Florida
Glioblastoma
View Study & Checklist βStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-NaΓ―ve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
π UAB Hospital β Birmingham, Alabama
Myelofibrosis
View Study & Checklist βOpen Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
π MD Anderson Cancer Center β Houston, Texas
Primary Myelofibrosis
View Study & Checklist βRuxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
T-cell Lymphoma
View Study & Checklist βIvosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
π University of Chicago Medicine Comprehensive Cancer Center β Chicago, Illinois
Myeloproliferative Neoplasms
View Study & Checklist βCART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
π Children's Hospital of Philadelphia β Philadelphia, Pennsylvania
Acute Myeloid Leukemia (AML)
View Study & Checklist βPhase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
π The University of Texas M. D. Anderson Cancer Center β Houston, Texas
T-cell Prolymphocytic Leukemia
View Study & Checklist βRuxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
π City of Hope Medical Center β Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist βEvaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
π National Institutes of Health Clinical Center β Bethesda, Maryland
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
View Study & Checklist βAddition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
π M D Anderson Cancer Center β Houston, Texas
Hematopoietic and Lymphoid Cell Neoplasm
View Study & Checklist βRuxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
π The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins β Baltimore, Maryland
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
View Study & Checklist βA Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
π Stanford Cancer Center β Palo Alto, California
Graft-versus-host Disease (GVHD)
View Study & Checklist βRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
π Children's Hospital of Colorado β Aurora, Colorado
Sickle Cell Disease
View Study & Checklist βRuxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
π Univ of Miami - Sylvester Comprehensive Cancer Center β Miami, Florida
Chronic Graft-versus-host Disease (cGVHD)
View Study & Checklist βRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
π University of California, Irvine β Irvine, California
Hemophagocytic Lymphohistiocytoses
View Study & Checklist βPhase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
π The University of Texas M. D. Anderson Cancer Center β Houston, Texas
Myelofibrosis (MF)
View Study & Checklist βA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
π Memorial Sloan Kettering Basking Ridge β Basking Ridge, New Jersey
Myelofibrosis Due to and Following Polycythemia Vera
View Study & Checklist βA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naΓ―ve Myelofibrosis and Moderate Thrombocytopenia
π City of Hope - Duarte Main Site β Duarte, California
Myelofibrosis
View Study & Checklist βRuxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Myelodysplastic/Myeloproliferative Neoplasm
View Study & Checklist βDose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Leukemia
View Study & Checklist βA Vaccine (VSV-hIFNΞ²-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
π Mayo Clinic in Arizona β Scottsdale, Arizona
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist βDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Acute Myeloid Leukemia
View Study & Checklist β